Most Popular in:
New Melanoma Drug Sees Success
Posted: June 1, 2009
page 2 of 2
Dr. Flaherty, who presented the results at a meeting of the American Society of Clinical Oncology, said future trials will only enroll patients who test positive for the mutation.
Other drugs in development which target BRAF pathway mutations include XL281 from Exelixis Inc and RAF265 from Novartis AG.